Suppr超能文献

是否应对所有患者凝血因子检测进行多因素稀释?让辩论开始吧!

Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

作者信息

Favaloro Emmanuel J, Pasalic Leonardo

机构信息

Department of Haematology Institute of Clinical Pathology and Medical Research (ICPMR) NSW Health Pathology Westmead Hospital Westmead New South Wales Australia.

Sydney Centres for Thrombosis and Haemostasis Westmead New South Wales Australia.

出版信息

Res Pract Thromb Haemost. 2022 Mar 13;6(2):e12689. doi: 10.1002/rth2.12689. eCollection 2022 Feb.

Abstract

Laboratory assessment of blood coagulation factors may be undertaken for various reasons, including investigating the possibility of hemophilia or unexpected prolongation in routine coagulation assays (eg, prothrombin time, activated partial thromboplastin time). Several guidelines recommend performing multiple dilutions (usually 2-3) on all patient test samples to evaluate "parallelism" as a guide to the presence of potential "inhibitors," be they factor inhibitors, lupus anticoagulant, or related to the presence of anticoagulant therapy. The current Forum argues against mandating investigation of parallelism (or multiple dilutions) for all samples destined for testing, instead suggesting that a more targeted approach will likely provide better clinical utility and use of laboratory resources.

摘要

出于各种原因,可能会对血液凝固因子进行实验室评估,包括调查血友病的可能性或常规凝血检测(如凝血酶原时间、活化部分凝血活酶时间)中意外延长的情况。一些指南建议对所有患者检测样本进行多次稀释(通常为2 - 3次),以评估“平行性”,作为潜在“抑制剂”存在的指导,无论这些抑制剂是因子抑制剂、狼疮抗凝物,还是与抗凝治疗的存在有关。当前的论坛反对对所有待检测样本强制进行平行性调查(或多次稀释),而是建议采用更具针对性的方法可能会提供更好的临床效用并更合理地利用实验室资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a5/8918913/69bc3954ed23/RTH2-6-e12689-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验